Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $109.21M.
ENTERPRISE VALUE (EV)
$109.21M
Insight Molecular Diagnostics Inc.
Market Cap
$120.80M
Enterprise Value (EV)
$109.21M
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | $120.80M | $109.21M |
| TuHURA Biosciences, Inc. (HURA)vs › | $122.20M | $121.61M |
| Caribou Biosciences, Inc. (CRBU)vs › | $118.42M | $118.88M |
| BGM Group Ltd. (BGM)vs › | $117.87M | $107.52M |
| Genelux Corporation (GNLX)vs › | $117.48M | $110.72M |
| enGene Holdings Inc. (ENGN)vs › | $124.27M | $116.51M |
| Foghorn Therapeutics Inc. (FHTX)vs › | $115.67M | $90.69M |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $115.44M | $42.27M |
| LENZ Therapeutics, Inc. (LENZ)vs › | $114.76M | $90.67M |
| Coya Therapeutics, Inc. (COYA)vs › | $114.35M | N/A |
Market Cap
$120.80M
Total Debt
$0.00
Cash
$11.58M
Enterprise Value
$109.21M
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
